EGFRvIII-STAT3 signaling is important in glioblastoma pathogenesis. Here, we identified the cytokine receptor OSMR as a direct target gene of the transcription factor STAT3 in mouse astrocytes and human brain tumor stem cells (BTSCs). We found that OSMR functioned as an essential co-receptor for EGFRvIII. OSMR formed a physical complex with EGFRvIII, and depletion of OSMR impaired EGFRvIII-STAT3 signaling. Conversely, pharmacological inhibition of EGFRvIII phosphorylation inhibited the EGFRvIII-OSMR interaction and activation of STAT3. EGFRvIII-OSMR signaling in tumors operated constitutively, whereas EGFR-OSMR signaling in nontumor cells was synergistically activated by the ligands EGF and OSM. Finally, knockdown of OSMR strongly suppressed cell proliferation and tumor growth of mouse glioblastoma cells and human BTSC xenografts in mice, and prolonged the lifespan of these mice. Our findings identify OSMR as a critical regulator of glioblastoma tumor growth that orchestrates a feed-forward signaling mechanism with EGFRvIII and STAT3 to drive tumorigenesis. 
a r t I C l e S
Glioblastoma is the most common malignant primary brain tumor in adults. Despite advances in understanding the molecular mechanisms underlying these tumors, current treatments are ineffective [1] [2] [3] [4] [5] . Therefore, there is an urgent need to better understand the pathogenesis of these devastating tumors.
Glioblastoma tumors are thought to arise from astrocytes and their precursors, neural stem cells [6] [7] [8] [9] [10] . Regardless of the cell of origin, the resulting tumors are a heterogeneous population composed of both undifferentiated and differentiated cells and contain a subpopulation of tumorigenic self-renewing BTSCs [11] [12] [13] [14] . The identification of BTSCs within glioblastoma tumors has raised intense interest in the identification of mechanisms that regulate the tumorigenic property of these cells.
Among frequent genetic alterations identified in glioblastoma tumors are activating mutations of epidermal growth factor receptor (EGFR), which transform both immortalized mouse astrocytes and neural stem cells into malignant tumor cells 4, 7, [15] [16] [17] . The most common active mutant of EGFR in glioblastoma is a truncated EGFR in which exons 2−7 are deleted (EGFRvIII) 16 . EGFRvIII is a constitutively active receptor that in the absence of epidermal growth factor (EGF) induces the phosphorylation of STAT3 to drive tumorigenesis 17, 18 . However, the mechanisms by which STAT3 drives glial cell transformation and the malignant behavior of human BTSCs in the background of EGFR activation remain poorly understood. In this study, we identified the cytokine receptor OSMR as a critical component of EGFRvIII-STAT3 signaling that triggers a feed-forward signaling mechanism to drive the pathogenesis of glioblastoma.
RESULTS

EGFRvIII-STAT3 transcriptional targets in glioblastoma
To facilitate identification of differentially expressed genes induced by EGFRvIII-STAT3 signaling in human BTSCs, we performed RNA sequencing (RNA-seq) analysis of three EGFRvIII-expressing BTSC lines: BTSC68, BTSC73 and BTSC90 (Supplementary Tables 1,2 , and Supplementary Fig. 1a-c) . As a control, we performed RNA-seq on a BTSC line that does not express EGFRvIII, BTSC41. Differentially expressed genes in each of BTSC68, BTSC73 and BTSC90 lines were called relative to the BTSC41 control by Tophat/Cufflinks RNAseq analysis pipeline. Intersection of differentially regulated genes in each of the EGFRvIII-expressing BTSCs was obtained, and 272 common candidate targets were identified in human BTSCs (Fig. 1a,  Supplementary Fig. 1c,d and Supplementary Tables 3 and 4).
To identify candidate target genes of EGFRvIII-STAT3 signaling in astrocytes specifically in an EGFRvIII-or STAT3-dependent manner, we used a genetic mouse model. We analyzed EGFRvIII-expressing or control MSCV-infected astrocytes that expressed Stat3 (Stat3 loxP/loxP ) a r t I C l e S or in which Stat3 was conditionally deleted (Stat3 −/− ) by RNA-seq ( Supplementary Fig. 1e ). We established differentially regulated genes in an EGFRvIII-and STAT3-dependent manner. Most genes that were highly induced in a STAT3-dependent manner in EGFRvIIIexpressing astrocytes displayed little or no induction in response to STAT3 in the absence of EGFRvIII expression (Fig. 1b) .
In parallel, we used chromatin immunoprecipitation followed by massively parallel sequencing (ChIP-seq) to identify genomewide sites of STAT3 occupancy in the background of EGFRvIII expression. We defined high-confidence STAT3 binding sites (STAT3 peaks) based on STAT3 motif and conservation scores ( Fig. 1c and Supplementary Fig. 2a−d) . In analyzing the genomic distribution of STAT3 ChIP-seq peaks relative to the STAT3 differentially regulated genes, we found that STAT3 operates primarily as a transcriptional activator in EGFRvIII-expressing astrocytes (Fig. 1d,e) and that STAT3 peaks were most abundant in the 5′ untranslated region (UTR) and promoter relative to genes ( Fig. 1d and Supplementary Fig. 2e,f) .
To identify EGFRvIII-STAT3 direct target genes that might have a role in the pathogenesis of glioblastoma, we focused on target genes with the following features: (i) STAT3 occupancy of the promoter or 5′ UTR, (ii) upregulated expression in a STAT3-dependent manner, (iii) conservation of STAT3 ChIP-seq peaks and STAT3 binding motifs across 20 placental mammals within ± 5 kilobases (kb) of the transcription start site (TSS), and (iv) differential expression in the same direction in all EGFRvIII-expressing human BTSCs and mouse astrocytes.
OSMR, EGFRvIII and STAT3 share a common gene network RNA-seq analyses revealed that OSMR was highly expressed in all EGFRvIII-expressing human BTSCs and mouse astrocytes ( Supplementary Fig. 1c,e) . ChIP-seq analyses revealed that STAT3 robustly occupied the promoter of the OSMR gene ( Supplementary  Fig. 3e ). In analyses of gene expression of human glioblastoma tumor samples deposited in The Cancer Genome Atlas (TCGA) and REMBRANDT databases, upregulation of both STAT3 and OSMR in human glioblastoma patients correlated significantly with worse patient prognosis (Fig. 2a,b and Supplementary Fig. 3a,b) , suggesting that OSMR may be a critical STAT3 target gene in the pathogenesis of human glioblastoma. In performing multivariate analyses using two independent approaches of Cox proportional hazards and stratified logrank test, we found that there was significant association of OSMR and STAT3 upregulation with reduced survival in glioma patients even when taking into consideration IDH1 mutation status, patient age and tumor grade (P < 0.01, Supplementary Fig. 3c,d ). These analyses suggest that the expression levels of OSMR and STAT3 are important predictors of survival.
We confirmed by ChIP followed by quantitative PCR (ChIPqPCR) that STAT3 directly occupied the promoter of the OSMR gene in human BTSCs expressing EGFRvIII or exhibiting high levels of phosphorylated STAT3 (Fig. 2c,d, Supplementary Table 1) . Likewise, STAT3 directly occupied the promoter of the Osmr gene in EGFRvIII-expressing mouse astrocytes (Supplementary Fig. 3f) . Deletion of Stat3 resulted in profound reduction in the levels of OSMR protein and Osmr mRNA in EGFRvIII-expressing astrocytes ( Supplementary Fig. 3g,h) . Knockdown of Stat3 in BTSC73 cells using a lentiviral-mediated RNA interference approach triggered the downregulation of Osmr mRNA levels (Supplementary Fig. 3i ). Immunoblotting analyses showed that OSMR protein expression was also higher in EGFRvIII-expressing human BTSCs and mouse astrocytes, compared to BTSCs and astrocytes that did not express EGFRvIII (Supplementary Figs. 1a and 3g) . Taken together, these data support the conclusion that OSMR is a direct EGFRvIII-STAT3 target gene.
We next characterized the landscape of OSMR target genes in the background of EGFRvIII expression. We performed RNA-seq analyses on two different OSMR knockdown (OSMR-KD1 and OSMR-KD2) and two control (scramble small hairpin (sh)RNA control and vector control) EGFRvIII-expressing astrocyte lines. We established a r t I C l e S OSMR-regulated genes and compared them with STAT3-and EGFRvIII-dependent candidate target genes. We found significant overlap between OSMR-dependent and STAT3-dependent or EGFRvIII-dependent targets (89 and 44 genes, respectively; Fig. 2e,f) . These results suggest that OSMR is a positive feed-forward signal with the EGFRvIII-STAT3 pathway in glioblastoma pathogenesis.
EGFRvIII and OSMR are co-receptors Our finding that OSMR has a common network of target genes with EGFRvIII led us to the hypothesis that OSMR and EGFRvIII form a co-receptor complex. Immunohistochemical analyses using OSMR and EGFRvIII antibodies revealed that these two proteins co-localized at the membrane ( Supplementary Fig. 4a,b) . OSMR is thought to associate with gp130 to form a high-affinity receptor for its ligands 19 . Therefore, we immunoprecipitated lysates of EGFRvIII-expressing BTSCs or astrocytes using an OSMR antibody followed by immunoblotting with EGFR, EGFRvIII and gp130 antibodies. We found that OSMR interacted with EGFRvIII endogenously in both mouse astrocytes and human BTSCs (Fig. 3a,b) . However, we did not detect the interaction of endogenous OSMR with gp130 or wild-type EGFR in EGFRvIII-expressing human BTSCs and mouse astrocytes (Fig. 3a,b and Supplementary Fig. 4c ). To confirm the EGFRvIII-OSMR interaction in situ, we used a proximity ligation assay (PLA) with antibodies recognizing OSMR or activated EGFR that is phosphorylated on Tyr1068. We found that endogenous OSMR interacted with phosphorylated EGFR-Y1068 and EGFRvIII in EGFRvIII-expressing human BTSCs (Fig. 3c) compared to the non-EGFRvIII-expressing control human BTSC12 and BTSC139 lines (Fig. 3d) .
EGFRvIII may induce secretion of cytokines resulting in gp130 activation in a paracrine fashion to maintain tumor growth and heterogeneity in mixed composition glioblastoma tumors 20 Fig. 4d ,e). Knockdown of gp130 or EGFR had little or no effect on the EGFRvIII-OSMR interaction (Supplementary Fig. 4f ). Further, STAT3 activation was not reduced in EGFRvIII-expressing astrocytes upon knockdown of genes encoding gp130 or wild-type EGFR (Supplementary Fig. 4g ). These data suggest that gp130 and wild-type EGFR are not required for the interaction of EGFRvIII with OSMR.
Next, we characterized the role of oncostatin M (OSM), the ligand for OSMR, in signal transduction by the EGFRvIII-OSMR co-receptor complex. We analyzed tumorigenic GFP-EGFRvIII-expressing and non-tumorigenic GFP-MSCV-expressing control astrocytes treated with OSM or EGF by PLA to examine the association of EGFR or EGFRvIII with OSMR. In EGFRvIII-expressing astrocytes, we detected the association with OSMR in the absence of OSM or EGF treatment (Fig. 3e,i) . In the absence of ligand treatment, PLA did npg a r t I C l e S not reveal interaction between OSMR and EGFR in MSCV-infected control astrocytes ( Fig. 3f,i) . By contrast, OSM treatment stimulated robust interaction of OSMR with EGFR in the control astrocytes ( Fig. 3g,i) . Notably, EGF treatment was not sufficient to stimulate the EGFR-OSMR interaction in astrocytes (Fig. 3h,i) . Because OSM is required to trigger the interaction of OSMR with EGFR in astrocytes that do not express oncogenic EGFRvIII, we assessed the influence of OSM on EGFR and STAT3 signaling in these cells. Treatment of MSCV-control astrocytes with OSM robustly induced the activation of EGFR as reflected by its phosphorylation at Y1068, and led to the activation of STAT3 as detected by phosphorylation of STAT3 at Tyr705 and Ser727 ( Fig. 4a and Supplementary Fig. 5a−e) . The functional consequence of OSM addition to non-tumorigenic MSCV-expressing astrocytes was a significant increase in the proliferative capacity of these cells as quantified by Ki67 staining (unpaired Student's t test, two-tailed distribution, P = 0.01, n = 3, Supplementary Fig. 5f−h ). The addition of OSM and EGF induced the synergistic phosphorylation of STAT3 at Ser727 in wild-type astrocytes (Fig. 4b,c and Supplementary  Fig. 5e ). These results support the conclusion that activated/ phosphorylated EGFR and OSMR function in a complex to regulate cell growth and that OSM signaling induces the phosphorylation of EGFR, leading to the EGFR-OSMR interaction. We next addressed the question of whether phosphorylation of EGFR or of EGFRvIII is required for the OSMR-EGFRvIII interaction. We determined the effect of two pharmacological inhibitors of EGFR-EGFRvIII phosphorylation, canertinib and lapatinib, on the EGFRvIII-OSMR interaction in astrocytes. We first confirmed that both inhibitors substantially attenuated the phosphorylation of EGFRvIII (Fig. 4d) . The addition of either inhibitor impaired the binding of EGFRvIII to OSMR (Fig. 4e, lapatinib treatment) and the phosphorylation of STAT3 (Fig. 4d) . These results suggest that the phosphorylation of EGFRvIII may regulate its binding with OSMR and that the EGFRvIII-OSMR interaction in the absence of ligand occurs owing to the constitutive phosphorylation of EGFRvIII. Conversely, exposure of wild-type astrocytes to exogenous OSM is required to trigger an increase in the phosphorylation of EGFR and consequently its interaction with OSMR, and STAT3 signaling. Knockdown of OSMR substantially reduced the levels of EGFRvIII (Fig. 4f) , suggesting that OSMR may also control the stability of EGFRvIII in addition to its phosphorylation status. Accordingly, knockdown of OSMR also substantially reduced the phosphorylation of STAT3 at the key regulatory sites Tyr705 and Ser727 (Fig. 4f) suggesting that OSMR is required to maintain STAT3 signaling in EGFRvIII-expressing astrocytes. Taken together, our data indicate that EGFRvIII and OSMR are obligate co-receptors. Full-length blots are presented in Supplementary Figure 7 . (e) GFP-EGFRvIII-expressing astrocytes that were treated with lapatinib were subjected to PLA of OSMR and EGFRvIII as described in Figure 3 . Images are representative of six random fields across two independent slides. Scale bars, 10 µm. (f) EGFRvIIIexpressing mouse Osmr-KD1, -KD2, and vector control (CTL) astrocytes were analyzed by immunoblotting. P-STAT3-Y705 and P-STAT3-Ser727 antibodies were used to assess STAT3 phosphorylation. The p-EGFR-Y1068 antibody was used to examine EGFRvIII and EGFR phosphorylation levels. EGFRvIII antibody is used to detect total EGFRvIII levels. Tubulin was used as loading control. Full-length blots are presented in Supplementary Figure 7 . The blots represent a minimum of three technical replicates from different passage number for each cell line. In all blots, total EGFR and EGFRvIII are indicated with * and **, respectively.
OSMR stimulates the proliferation of BTSCs and astrocytes
Since EGFRvIII-STAT3 signaling has a key role in the regulation of cell growth, we examined the role of OSMR in the regulation of cell growth. We generated three different OSMR knockdown BTSC73 lines by lentivirus-mediated delivery of three independent shRNAs targeting OSMR mRNA. We confirmed that each of the three shRNAs induced the efficient knockdown of endogenous OSMR, reducing OSMR mRNA levels by 65−77% in BTSC73 cells (Supplementary Fig. 6a,b) . We found that the knockdown of OSMR significantly reduced the population growth of EGFRvIII-expressing BTSC73 cells (Fig. 5a,b) . 
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Expression of EGFRvIII typically occurs in glioblastoma tumors where EGFR is amplified [21] [22] [23] . We found that STAT3 also directly bound the promoter of OSMR in human BTSCs in which STAT3 is highly phosphorylated (Fig. 2d and Supplementary Fig. 6c) , and analyses of the proteomic data at TCGA database revealed a positive correlation between the phosphorylation of EGFR/ EGFRvIII at Tyr1068 with the phosphorylation of STAT3 at Tyr705 (Supplementary Fig. 6d ). We therefore assessed the impact of OSMR knockdown on cell growth in BTSC145 cells that exhibit a high level of phosphorylated STAT3 using three OSMR knockdown lines (OSMR-KD1, OSMR-KD2 and OSMR-KD3). OSMR knockdown led to significant reduction in population growth of BTSC145 cells (Fig. 5c) .
We next assessed whether OSMR regulates the proliferation of mouse astrocytes upon activation of EGFRvIII-STAT3 signaling. We used two short hairpin RNAs (shRNAs) targeting mouse Osmr mRNA that substantially reduced Osmr mRNA and OSMR protein levels in EGFRvIII-expressing astrocytes ( Supplementary  Fig. 6e−g ). We found that the growth of EGFRvIII-expressing astrocytes was significantly reduced upon Osmr knockdown (Fig. 5d) . Moreover, the percentage of Ki67-positive astrocytes was significantly reduced upon Osmr knockdown (Fig. 5e and  Supplementary Fig. 6h ).
OSMR is required for glioblastoma tumor growth Our discovery of OSMR as a critical component of EGFRvIII-STAT3 signaling raised the question of whether OSMR regulates tumor growth in vivo. To determine the role of OSMR in tumorigenicity of human BTSCs in vivo, we subcutaneously injected two different OSMR knockdown or control BTSC73 lines, the latter infected with the scrambled shRNAs, into 6-week-old severe combined immunodeficient (SCID) mice and assessed the ability of these cells to form tumors in vivo. OSMR knockdown and control BTSC lines also expressed GFP, allowing confirmation that the tumors were initiated from the injected cells. Knockdown of OSMR in human BTSCs suppressed tumor growth by more than 80% (Fig. 6a-c) . Immunohistochemical analyses using Ki67 antibody revealed that OSMR knockdown substantially attenuated cell proliferation in BTSC73-derived tumors in vivo (Fig. 6d) .
To evaluate whether OSMR influences glial transformation in vivo, OSMR knockdown and control EGFRvIII-expressing astrocytes that also expressed GFP were injected subcutaneously into 6 week-old SCID mice. 2−3 weeks after injection, all mice in the control group harbored ulcerated tumors at the site of injection and had lost more than 20% of their body weight. We confirmed that the tumors initiated from the injected cells on the basis of GFP fluorescence (Fig. 6e,f) . Image is representative of 6 independent section from three different mice. (e) Osmr knockdown and control EGFRvIII-expressing astrocytes, which also expressed GFP, were injected into 6 week-old SCID mice and allowed to form tumors subcutaneously. Animals were collected 4 weeks after injections at which time all mice injected with control EGFRvIII-expressing astrocytes were at end stage with ulcerated tumors. Osmr-KD1 and -KD2 and corresponding control were subjected to optical imaging to trace and detect tumors before their collection. (f) GFP-positive tumors were imaged using a fluorescence microscope (Top panel). (g) Isolated tumors were weighed before fixation. Graph represents quantification of the tumor mass in Osmr knockdown and control EGFRvIII-expressing astrocytes. The significance of difference was analyzed using unpaired student t-test, two tail distribution. n = 6 mice for each group. CTL vs. KD1: P = 0.0001, t = 6.205, d.f. = 10; CTL vs. KD2: P = 0.0001, t = 9.338, d.f. = 10. ***P < 0.001. Error bars represent ± s.e.m. (h) Ki67 staining of tumor section is presented for control and OSMR-KD1 astrocytes. No tumors were formed by Osmr-KD2 astrocytes. Image represents analyses of 6 different slides from three different mice. Scale bars, 20 µm. (i,j) EGFRvIII-STAT3 loxP/loxP xenografts were subjected to immunohistochemistry using the Ki67 antibody or hematoxylin and eosin (H&E) staining to assess their characteristics. Scale bars, 5,000 µm; insets are at 80× magnification. Mitotic figures are shown with yellow arrows. Adipose tissue surrounding the tumor (brown arrows) is shown as negative control for Ki67 staining. Red arrow indicates necrotic area. Image represents slides from two independent mice. Blue arrow indicates tumor tissue. (k) Animals were injected with human BTSC73 cells and corresponding knockdown group as described in a. Each animal was collected at end stage. Kaplan-Meier survival plot was graphed to evaluate animal lifespan in each group. Black line, BTSC73-scrambled control, n = 4; Blue line: BTSC73-OSMR-knockdown, n = 6, P = 0.0001 by log rank test, P = 0.0003 by Gehan-Breslow-Wilcoxon test. npg a r t I C l e S We observed a dramatic reduction in tumor mass when EGFRvIII-expressing astrocytes were infected with an shRNAexpressing lentivirus to knock down Osmr (Fig. 6e-g ). EGFRvIII-expressing, astrocyte-derived tumors were highly malignant with numerous mitotic bodies, necrosis and high Ki67 immunoreactivity (Fig. 6i,j) . Similar to human BTSC73-derived tumors, immunohistochemical analyses of these tumors using Ki67 antibody showed that OSMR knockdown robustly attenuated cell proliferation in vivo (Fig. 6h) . Quantification of tumor mass 4 weeks after injection showed that OSMR knockdown significantly suppressed tumor mass in vivo (Fig. 6g) . The tumor-suppressive effect of OSMR knockdown correlated with the level of OSMR knockdown in the cells that had been injected (Supplementary Fig. 6f) . Depletion of OSMR in human glioblastoma cells prolonged lifespan of animals injected with these cells (Fig. 6k) . Taken together, these findings suggest that OSMR robustly influences the malignant transformation of EGFRvIII-expressing glial cells and human BTSC.
Having identified a critical role for OSMR in the malignant transformation and behavior of EGFRvIII-expressing mouse astrocytes and human BTSCs in vivo, we next asked whether OSMR contributes to tumorigenesis in the context of brain tissue in vivo. We injected intracranially EGFRvIII-expressing control and corresponding OSMR knockdown astrocytes into 6-week-old SCID mice. Mice injected with EGFRvIII-expressing control astrocytes formed brain tumors that were harvested when the animals were at end stage of disease and displayed a loss of body weight and neurological signs (Fig. 7a  and data not shown) . OSMR knockdown mice were collected at the same time for histological analyses. The tumors in the control animals were clearly derived from injected cells on the basis of GFP expression (Fig. 7b) . Animals were also screened for the presence and absence of tumor by magnetic resonance imaging (MRI). In the imaging analyses, we detected tumors in all the animals injected with EGFRvIII-expressing astrocytes, but observed no tumors in animals injected with EGFRvIII-expressing OSMR knockdown astrocytes (Fig. 7c) . Immunohistochemical analyses revealed the presence of highly malignant tumors in all brains injected with control EGFRvIIIexpressing astrocytes (Fig. 7d-e) . By contrast, no mitotic bodies, necrosis, hyper-proliferation or tumor mass were observed in the npg a r t I C l e S animals injected with OSMR knockdown EGFRvIII-expressing astrocytes. These results establish that depletion of OSMR impedes brain tumor growth.
DISCUSSION
In this study, we discovered that the cytokine receptor OSMR is a required co-receptor of EGFRvIII that has a prominent role in glioblastoma tumorigenesis. We found that OSMR is a highly upregulated direct transcriptional target gene of STAT3 in glioblastoma. OSMR forms a complex with EGFRvIII to regulate STAT3 activation and its transcriptional output. Loss of OSMR impairs EGFRvIII function, STAT3 activation and brain tumor formation. Our study identified OSMR as a critical component of EGFRvIII-STAT3 signaling that forms a feed-forward signaling mechanism with these molecules to drive oncogenesis. The transcription factor STAT3 exerts a dual role in glioblastoma tumors depending on the genetic background 17, 24 . In the absence of the major oncogenic protein EGFRvIII, STAT3 has a tumorsuppressive role 17 . Further, STAT3 has an instructive role in astrocyte differentiation during neural precursor development 25 . However, expression of the oncogenic protein EGFRvIII triggers a switch, whereby STAT3 exerts a potent oncogenic function in glioblastoma 17, 26, 27 . We found that EGFRvIII-OSMR complex signals to activate STAT3, and STAT3 signals to upregulate OSMR expression. The result is a feed-forward signaling mechanism that drives oncogenesis. Accordingly, OSMR has a critical role in the mechanism that drives glioblastoma tumor progression.
In characterizing the underlying molecular mechanisms by which OSMR promotes EGFRvIII-STAT3 signaling, we found that the phosphorylation of EGFRvIII is required for binding to OSMR. Inhibition of EGFRvIII phosphorylation by lapatinib and carnatinib strongly impaired the EGFRvIII-OSMR interaction and STAT3 activation. Conversely, OSM has a critical role in EGFR phosphorylation, its interaction with OSMR and consequently STAT3 activation. We also observed that knockdown of OSMR attenuates EGFRvIII levels in EGFRvIII-expressing astrocytes. Together, our results suggest that EGFRvIII and OSMR are obligate co-receptors in maintaining oncogenic STAT3 signaling. Collectively, our findings suggest that OSMR and activated EGFR are components of a physical co-receptor complex that functionally cooperate to activate a common repertoire of target genes in glioblastoma tumors.
Wild-type EGFR has been reported to participate in the phosphorylation of EGFRvIII in glioma cell lines with EGFRvIII and EGFR overexpressed, though no direct interaction of EGFR and EGFRvIII has been reported in co-immunoprecipitation analyses of these cells 21, 23 . In the present study, we did not detect an interaction between EGFR and EGFRvIII in human BTSCs or mouse astrocytes that expressed EGFRvIII. In light of these observations, it will be important in future studies to assess whether OSMR might facilitate the intimate relationship between wild-type EGFR and EGFRvIII in glioma cells with mixed composition.
Our findings reveal that the interaction of OSMR with wild-type EGFR is triggered by the ligand OSM in non-tumorigenic cells, suggesting that OSMR forms a co-receptor with wild-type EGFR in response to environmental cues. OSM is a multifunctional cytokine that is typically produced by white blood cells, but the production of OSM in cancer is thought to occur in the tumor stroma, suggesting the existence of cross-talk between the tumor stroma and cancer cells 28 . OSMR upregulation appears to confer increased sensitivity to OSM in cervical squamous carcinoma cells 29 .
In conclusion, we identified a key mechanism that contributes to glioblastoma tumor progression. OSMR is a cell surface receptor that defines a feed-forward mechanism with EGFRvIII and STAT3 in glioblastoma pathogenesis, and thus represents an attractive target for the development of therapeutics. In particular, a screen for small molecules that either inhibit OSMR activity or its interaction with activated EGFR may prove valuable in identifying new drugs to mitigate the malignant behavior of glioblastoma tumors.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Gene Expression Omnibus (GEO) accession codes for 12 RNA-seq and 2 ChIP-seq data sets are provided in Supplementary Table 2 and are available under series GSE51281. a r t I C l e S subcutaneously into 6-week-old male SCID mice. Mice were killed, and the tumors were removed, measured and fixed for histological analyses at the time they developed neurological signs and ulcerated tumors. For KaplanMeier survival plots, mice were collected at the time they were at end stage. Median survivals were determined by a log-rank test using GraphPad Prism as described previously 32 . For intracranial injections, 3 × 10 5 EGFRvIIIexpressing OSMR-KD1, -KD2 and corresponding control were redissolved in serum-free medium and were stereotactically implanted into the right striata of 6-week-old male SCID mice. Animals were killed after 4 weeks of injections. Brains were removed, fixed in 10% formalin, and prepared for histology and immunohistochemistry analyses. MRI and cranial dissection were performed to confirm presence of tumor.
Statistical analyses. Analyses for high-throughput sequencing data are described above. Statistical analyses for TCGA and REMBRANDT database are described above. Statistical analyses for functional and biochemical in vitro and in vivo studies were performed using two-tailed distribution unpaired Student t-test. All dot plots were generated by Graphpad Prism 6. All histograms were presented as mean ± s.e.m. P values of equal or less than 0.05 were considered significant and are marked with an asterisk on the histogram. P values of less than 0.01 are denoted by **, and P values of less than 0.001 are denoted by *** on the histograms. Median survival data were determined by a log-rank test using GraphPad Prism as described previously 32 . No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those generally used in the field. Data distribution was assumed to be normal, but this was not formally tested. Blinding and randomization was performed on all counting experiments including cell number quantification, Ki67 staining, and PLA signal quantification, and survival data analyses.
A Supplementary methods checklist is available.
